ASTCT Pharmacy SIG Journal Club Session – May 11, 2022

PRESENTERS & ARTICLES

Arthur Nguyen  
PGY-2 Oncology Pharmacy Resident  
Oregon Health and Science University  
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma  

Elizabeth A. Meszaros, PharmD  
PGY-2 Hematology/Oncology Pharmacy Resident  
South Texas Veterans Healthcare System  
- Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial  
  https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2021005847/483954/Posttransplant-Cyclophosphamide-for-Prevention-of

Session Learning Objectives:  
Upon completion of the activity, participants should be able to:  
1. Evaluate the safety and efficacy of Axicabtagene Ciloleucel for the treatment of large B-cell lymphomas (LBCL).  
2. Review current standards of care for Graft-versus-Host Disease (GVHD) prevention for Matched Related Donors (MRD) and Matched Unrelated Donor (MUD) peripheral blood allogeneic hematopoietic stem cell transplants (alloHSCT).  
3. Evaluate the utility of post-transplant cyclophosphamide (PTCy) combined with a short course of cyclosporine (CsA) as compared to mycophenolic acid (MPA) with CsA for GVHD prophylaxis in patients receiving MRD and MUD peripheral blood alloHSCT.

TARGET AUDIENCE  
This activity is intended for pharmacists.

ACCREDITED PROVIDER  
This activity is jointly provided by The France Foundation and ASTCT.
The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a posttest (>75%). There is no fee to participate in this activity. This is a knowledge-based educational activity. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.

ACPE No. UAN: 0391-9999-22-044-L01-P.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures

The individuals listed below disclosed the following relevant financial relationships:

<table>
<thead>
<tr>
<th>Name of Individual</th>
<th>Individual's Role in Activity</th>
<th>Name of Commercial Entity</th>
<th>Nature of Relationship(s)</th>
<th>Mechanism(s) implemented to resolve conflict of interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur Nguyen, PharmD</td>
<td>Faculty</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Elizabeth A. Meszaros, PharmD</td>
<td>Faculty</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Haedyn Smith</td>
<td>ASTCT Staff</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Heather Tarbox, MPH</td>
<td>TFF Staff</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Jas Chahal, PhD</td>
<td>TFF Staff</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Ted Bruno, MD</td>
<td>TFF Staff, Content Reviewer</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
DISCLOSURE OF UNLABELED USE
TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER
TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

CONTACT INFORMATION
If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.